# Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts

> **NCT00058812** · PHASE1 · COMPLETED · sponsor: **Baylor College of Medicine** · enrollment: 69 (actual)

## Conditions studied

- Epstein-Barr Virus Infections

## Interventions

- **BIOLOGICAL:** EBV specific T cells

## Key facts

- **NCT ID:** NCT00058812
- **Lead sponsor:** Baylor College of Medicine
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 1993-05
- **Primary completion:** 2014-07
- **Final completion:** 2014-07
- **Target enrollment:** 69 (ACTUAL)
- **Last updated:** 2015-01-29

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00058812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00058812, "Giving Epstein-Barr Virus (EBV) Specific Killer T Lymphocytes to Patients Who Have Had Donor Marrow Grafts". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00058812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*